Skip to Main Content

Editorial Board

Editor-in-Chief: Weiping Han

Affiliation: Agency for Science, Technology and Research, A*Star Institute, Singapore

Biography: Weiping Han obtained his Ph.D. in Physiology from Cornell University, and did his postdoctoral work at the University of Pittsburgh and HHMI/UT Southwestern Medical Center in Dallas. In 2005, he moved to Singapore to set up a research program in the Laboratory of Metabolic Medicine (LMM) at Singapore Bioimaging Consortium (SBIC), and was promoted to Research Director / Professor in 2013. Currently he is Deputy Director of SBIC with concurrent appointment as Head of LMM. He is also Research Director at Institute of Molecular and Cell Biology; Professor in the Department of Biochemistry at National University of Singapore and Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School. His research interest is on the biological basis of metabolic diseases and associated complications.

Deputy Editor-in-Chief: Christoper Cooper

Affiliation: University of Huddersfield, UK

Biography: Following my first degree in Biochemistry at the University of Oxford (Merton College), I moved to the Department of Engineering Science and Linacre College to pursue a PhD/DPhil in molecular microbiology and biochemistry. During this time I developed an interest in DNA replication and repair studying thermacidophilic archaea and their DNA polymerases. To pursue my interests in genomics, I then undertook a Masters degree in Bioinformatics at the University of York with a research placement at the University of Uppsala in Sweden. I subsequently moved into eukaryotic molecular biology, working for 3 years at the Nuffield Department of Clinical Laboratory Sciences in Oxford. Here I researched microRNA and cancer-testis antigen expression profiles in human lymphomas, cementing my interests in cancer research. I then undertook two postdoctoral positions at the Structural Genomics Consortium (Oxford), working on high-throughput crystallography and biochemistry of human DNA polymerases and helicases involved in genome integrity, SNF2 family members in remodelling and ETS transcription factors. I continued to research genome integrity factors in cancer during a short postdoc at the Sir William Dunn School of Pathology (Oxford), using structural, biochemical and cell biology approaches to study endonucleases and chromatin remodelling SNF2 ATPases involved in the DNA damage response. During my latter postdoc positions I was appointed as an E.P. Abraham Cephalosporin Junior Research Fellow and a member of the Governing Body at Linacre Collegem and also as a College Lecturer in Biochemistry at the Queen's College. I joined the University of Huddersfield as a Senior Lecturer in Biological Sciences in 2015.

Associate Editors

Edward Bolt
Affiliation: University of Nottingham, UK
Biography: Edward’s lab is located in the medical school of QMC, University of Nottingham, where they research DNA repair and CRISPR-Cas immunity. Prior to his current position, Ed was a PI as a Wellcome Trust funded Research Career Development Fellow, also at Nottingham, after 5 years as a post-doc working on bacterial DNA repair. His PhD was at the University of London (UCL and QMUL) researching the enzymology of a key step in tetrapyrrole biosynthesis. He has strong collaborative links with several research establishments and universities internationally that allows his laboratory to combine genetics, biochemistry and structural analyses of DNA repair and CRISPR-Cas immunity. 

Kakoli Bose
Affiliation: Tata Memorial Centre, India
Biography: Programmed cell death or apoptosis poses an important impediment against cancer.  It is evident that effective treatment of cancer needs innovative identification of novel targets from the apoptotic pathway and their therapeutic intervention with greater efficacy and lower toxicity. Dr. Bose’s laboratory is committed toward this objective with her research interest being identification and characterization of targets in the apoptotic pathway so as to design modulators/analogs with desired characteristics using multidisciplinary approach. The group works on the high temperature requirement family of serine proteases (HtrA), the interaction between anti apoptotic c-FLIP and calmodulin as well as caspase-8 and FADD of extrinsic cell death pathway, and the Bcl2 family proteins and their interacting partners. Moreover, the group is now entering into application-based translation research that includes enzymes involved in metabolic reprogramming and their role in altering cancer signaling pathways.

Valerie Chew
Affiliation: Duke-NUS Medical School, Singapore
Biography: Dr. Valerie Chew graduated from National University Singapore and is current a principal investigator in Translational Immunology Institute (TII) and an assistant professor in Duke-NUS Medical School, Singapore. Dr Chew’s research focuses primarily on understanding the complexity and diversity of the immune context of the tumor microenvironment and its influence on clinical outcome or response to therapy in patients with hepatocellular carcinoma (HCC). Her current work involves high- and multi-dimensional immunophenotyping and immunomonitoring of HCC microenvironment with cutting edge multiplex and single-cell technologies such as Time of Flight Mass Cytometry (CyTOF) and next-generation sequencing (NGS). This powerful approach allows holistic profiling of immune landscapes and the identification of clinically relevant immune subsets or biomarkers predictive of tumour progression and response to therapy. Her work has gained recognition with multiple grant awards and high impact publications. 

Ricardo Correa
Affiliation: NCI-Designated Cancer Center, Sanford Burnham Prebys (SBP) Medical Discovery Institute, USA
Biography: Ricardo G. Correa, Ph.D., is a Pharmacist with over 20 years of scientific experience in Biochemistry and Molecular Biology, and previous industrial experience in the Development of Analytical Methods. Dr. Correa has a broad international scientific experience, working at well-recognized institutions like The Salk Institute (USA), University College London (UK) and Universidade de Sao Paulo (Brazil). Dr. Correa has fifteen years of research experience in cellular signaling pathways involving inflammation, tumorigenesis and immune response. During his Ph.D., Dr. Correa was nominated the first researcher to patent a novel human gene as potential tumor marker in Brazil. During his postdoctoral training, Dr. Correa characterized the role of NF-B in the zebrafish model and how this pathway impacts proliferative processes in vertebrates. After his post-doc, Dr. Correa was Assistant Professor at the University of Sao Paulo (USP) and the Pontificia Universidade Catolica (PUC) in Brazil. Later, Dr. Correa moved to La Jolla (CA, USA) to work at the SBP Medical Discovery Institute (SBMRI). His work has focused on innate immunity and cancer progression.

Anderly Chueh
Affiliation: The University of Melbourne, Australia
Biography: Dr Chüeh completed his undergraduate studies at The University of Melbourne majoring in Biochemistry and Genetics and PhD studies in Human Genetics at the Murdoch Children’s Research Institute (MCRI) where he performed pioneering research in the epigenetic regulation of centromere structure and function. In 2008 he joined the Ludwig Institute of Cancer Research (LICR) were he identified a novel clinically relevant transcriptional axis that is predictive of HDAC inhibitor drug sensitivity in tumour cells from multiple cancer types. Dr Chüeh was recruited to The Walter and Eliza Hall Institute (WEHI) in 2014 where lead target identification and MoA studies on first-in-class small molecule antimitotics that has demonstrated in vivo activities and licensed to commercial partners for co-development. Since 2016, Dr Chüeh has worked as a Senior Scientist contributing to high throughput screening, biomarker identification and target validation to multiple drug discovery pipelines in a leading Australian biotech company (Cancer Therapeutics CRC) that has successfully licensed novel small molecules to multinational pharmaceutical companies such as Merck and Pfizer. Dr Chüeh is an Associate Editor for UK Biochemical Society’s Biosciences Reports journal. He has published over 22 research articles in top-tier international cancer research and human genetics journals and won numerous awards.   

Amanda Coutts

Affiliation: Nottingham Trent University, UK

Biography: To be provided

Jean-Bernard Denault

Affiliation: Université de Sherbrooke, Canada
Biography: Jean-Bernard Denault is a professor at the Université de Sherbrooke, Québec, Canada, with a Ph.D. degree in Pharmacology. His research interests cover the mechanisms of regulation, activation, and activity of proteolytic enzymes, more specifically that of caspases during apoptosis. Dr. Denault's laboratory is interested in caspase biology with emphasis on their roles in cancer. His projects take advantage of protein engineering, enzymological characterization, gene manipulation, cancer cell models, structural biology, and other approaches to understand how caspases work and how these results can potentially lead to the development of new strategies to modulate their activity.

Karla Feijs
Affiliation: RWTH Aachen University, Germany
Biography:Karla obtained a BSc from the University of Maastricht, followed by an MSc from the University of Amsterdam with a major in oncology. For her MSc she pursued a research project investigating the role of ubiquitination in the Notch pathway at the Netherlands Cancer Institute. Subsequently, she obtained her PhD from RWTH Aachen University in biochemistry for work on the ADP-ribosyltransferase PARP10. Supported by an EMBO Fellowship, she performed postdoctoral work to study the enzymes MacroD1, MacroD2 and TARG1 at the Sir William Dunn School of Pathology in Oxford. Following a maternity break, Karla then returned to RWTH Aachen University to start her own research group in the Department of Biochemistry and Molecular Biology. In contrast to the well-studied PARP1, several other enzymes of the PARP family are poorly characterised, as are the enzymes reversing ADP-ribosylation. We are interested in defining the function of these transferases and hydrolases in normal physiology as well as in pathologies such as cancer.

Lorna Fiedler
Affiliation: OxStem, UK
Biography: Lorna’s experience spans 15 years across biotech and academic sectors in the cardiovascular field. She joined OxStem, a regenerative medicine company, in 2017 and moved to the executive team September 2019. She also holds a visiting scientist position at Oxford University. Lorna is experienced in managing academic-industry partnerships, with strong expertise in cardiovascular cell biology and drug discovery. Lorna previously held a Research fellow and project manager position at the Duke-National University of Singapore Medical School, and led a team at Imperial College London that discovered a cardioprotective small molecule. She has previously held postdoctoral positions in vascular biology at UCL, Reading and Cardiff Universities and worked in the biotechnology sector developing complement-based therapeutics.

Claire Friel

Affiliation: University of Nottingham, UK

Biography: To be provided

Nicola K. Gray

Affiliation: University of Edinburgh, UK

Biography: To be provided

Subash Chandra Gupta
Affiliation: Institute of Science, Banaras Hindu University, India 
Biography: Dr. Subash Gupta is an Assistant professor at Department of Biochemistry, Institute of Science, Banaras Hindu University (BHU), India. His current research is focused on uncovering the mechanism by which acidic micro-environment promote cancer growth. His laboratory is also working on cancer chemoprevention and other projects to understand the role of cancer stem cells, exosomal microRNAs and long non-coding RNAs in regulating tumor development. He has been honored with prestigious national and international awards. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 60 journals.

Michael Huang
Affiliation: The University of Sydney, Australia
Biography: Michael is a Senior Research Fellow in the Faculty of Medicine and Health at the University of Sydney, Australia. He obtained a BSc (Bioinformatics) with 1st Class Honours from the University of Sydney, and received his PhD in the Department of Pathology, University of Sydney. Since 2013, Michael established a research group that focuses on the elucidation of molecular mechanisms in the pathogenesis of human iron and mitochondrial disorders, with a particular focus on the neurodegenerative and cardio-degenerative disorder, Friedreich’s ataxia, and the regulation of the systematic iron hormone, hepcidin. Michael’s research spans basic science to translational research that utilizes multidisciplinary approaches including bioinformatics, biostatistics, biochemistry, molecular biology, animal genetics and medical science. Michael’s work has been recognized by a collection of prestigious National and International Awards, including Society of Free Radical Research International Young Investigator Award, Rebecca L Cooper Medal and Prize, Sydney Medical School Dean’s Prize, Peter Bancroft Prize, etc. Finally, Michael has been invited to act as grant review panellist for National and International agencies, chaired International conference sessions and served on multiple Editorial Boards.

W. Eustace Johnson

Affiliation: University of Chester, UK

Biography: To be provided

Zaklina Kovacevic

Affiliation: University of Sydney, Australia

Biography: Dr. Kovacevic is a Senior Research Fellow in the Department of Pathology at the University of Sydney, where she leads the NDRG1 and Metastasis Research Group. Her team consists of 3 PhD students and a post-doctoral fellow. She holds 2 externally funded fellowships, including the NHMRC R.D. Wright Career Development Fellowship and the CINSW Career Development Fellowship. Her research focuses on understanding metastasis, identifying molecular markers that control this process and developing novel treatment strategies designed to inhibit metastatic progression. Throughout her career, she has published 71 journal articles/books in high quality international journals (31 as 1st/senior/co-senior author). Her achievements were recognized by a suite of awards and prizes, including Cancer Institute of NSW Premier’s Award for Outstanding Cancer Research Fellow of the Year 2016, Sydney Medical School Award for Excellence for Outstanding Early Career Researcher (2016), Rebecca L. Cooper Medal, Peter Bancroft Prize and invitations to present her work at 48 conferences.

Wei Li

Affiliation: Beijing Children's Hospital, China

Biography: To be provided

Frank Michelangeli

Affiliation: University of Chester, UK

Biography: To be provided

Amy L. Milton

Affiliation: University of Cambridge, UK

Biography: To be provided

Krishna Rajalingam 

Affiliation: Cell biology Unit, University Medical Center, Johannes Gutenberg University, Mainz, Germany

Biography: Krishnaraj Rajalingam is the head of the Cell Biology Unit and a full professor of Cell Biology at the University Medical Centre, Johannes Gutenberg University, Mainz, Germany. Krishna received his Ph.D (2004) in Molecular Cell biology from the Max Planck Institute for Infections Biology in Berlin, Germany. After a brief stint as a postdoc, he started his own lab at the Institute of Medical Radiology and Cell Research at the University of Würzburg. Since 2014, he is a tenured full professor of Cell Biology and holds a prestigious Heisenberg Professorship of the DFG, at the University Medical Center of JGU, Mainz. He is a recipient of Max Planck Research fellowships, BOGS stipend from Leopoldina, the prestigious Emmy Noether Fellowship from the DFG and a PLUS3 fellowship of the Boehringer Ingelheim Foundation. More recently he has been selected to be a fellow of the Gutenberg Research College. Krishna holds an adjunct faculty position at the School of Biotechnology, IIT Madras, India and is a faculty member of DKTK, Germany. He also holds a joint visiting research directorship at IMCB Singapore to co-ordinate “Cancer Library Initiative” a major public private partnership. Krishna’s lab focuses on understanding the molecular signalling machinery that drives fundamental cellular processes like cell division, cell death, cell migration and differentiation with explicit biomedical implications with a prime focus on Kinases and ubiquitin signalling machinery.

Sumit Sahni
Affiliation: University of Sydney, Australia
Biography: Dr Sahni has received his PhD in Medicinal Chemistry from the University of Illinois at Chicago in 2011. Currently, Dr. Sahni is appointed as a Research Fellow at the Northern Clinical School, University of Sydney, where he plays a pivotal leadership role in the Pancreatic Cancer Research Group. His team consists of 2 PhD and 1 Masters students. His research is focused on understanding the role of the autophagic pathway in pancreatic cancer progression and development of anti-cancer therapeutic strategies targeting autophagy. He is also involved in several research projects aimed at identifying biomarkers for pancreatic cancer diagnosis and progression. Throughout his career, he has published 53 journal articles in high quality international journals and has received >7600 citations. He has secured a number of research grants from prestigious granting bodies, such as Cancer Australia, National Breast Cancer Foundation and AMP Foundation.

Fraser Scott
Affiliation: University of Strathclyde, UK

Biography: Fraser obtained an MSci(Hons) in Chemistry from the University of Strathclyde in 2009, which was followed by a PhD under the supervision of Prof. Colin J. Suckling OBE, at the same institution awarded in 2012. His doctoral studies spanned computational and synthetic medicinal chemistry, and microbiology, focussed on developing Minor Groove Binders as novel anti-infective agents. During this time, Fraser also obtained a BA(Hons) in Mathematics and Statistics, and a BSc(Hons) in Computing with Mathematical Sciences, with the Open University. Following the completion of his doctorate in 2012, Fraser obtained a PGDE in Chemistry and an MEd in Education studies whilst embarking on a short career in Secondary School education in Scotland. In 2014 he returned to the research group of Prof. Colin J. Suckling OBE at the University of Strathclyde to take up a Post-Doctoral position that included project managing the, now commercial, Minor Grove Binder drug discovery project, alongside medicinal chemistry, chemical biology and microbiology investigations. During this time, Fraser also completed an MSc in Teaching and Learning in Higher Education and was employed as an associate lecturer in Mathematics by the Open University. Fraser is currently at the University of Strathclyde as a Chancellor's Fellow in the Department of Pure and Applied Chemistry.

Gautam Sethi
Affiliation: National University of Singapore, Singapore
Biography: After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Dr. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015.  The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-κB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than three hundred scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves on the Editorial Boards of several prestigious international journals.  


Jan Skoda
Affiliation: Faculty of Science, Masaryk University, Czech Republic
Biography: Dr. Skoda is an Assistant Professor at the Masaryk University and a Postdoctoral Researcher at the International Clinical Research Center (Brno, Czech Republic). He obtained his PhD (2016) in Molecular & Cellular Biology from the Masaryk University. After a post-doctoral research stay in the Michael Hogarty Laboratory at the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia in 2017, he joined The University of Sydney in 2018 to work on a melanoma project as a Postdoctoral Research Associate in the Discipline of Pathology and Bosch Institute. During this time, he was awarded the Sydney Medical School Early Career Researcher Kickstart Grant. In fall 2019, he then returned to Brno where he currently leads the Cancer Stem Cell Group in the Laboratory of Tumor Biology at the Masaryk University. His research focus comprises various aspects of cancer stem cell biology, especially investigating the role of pluripotency factors in tumorigenesis, targeting mitochondrial functions in cancer stem cells, and understanding the molecular roles of CD133 in cancer cell signaling.

Nathan Subramaniam

Affiliation: Queensland University of Technology, Brisbane, Australia

Biography: Professor Nathan Subramaniam received his PhD from Purdue University, W. Lafayette, Indiana, USA. He did his postgraduate research at the Department of Biochemistry, University of California at Davis, USA. He then joined the group of Prof Wanjin Hong at the Institute of Molecular and Cell Biology, Singapore, where he completed his postdoctoral training in cell biology and protein trafficking. He is currently Professor in Biomedical Sciences (Molecular Medicine) at the Queensland University of Technology, Brisbane, Australia, and leads the Liver Disease and Iron Disorders Research Group at the Institute of Health and Biomedical Innovation and School of Biomedical Sciences. Professor Subramaniam’s interests lie in the study of liver disease and how the liver regulates iron homeostasis. His research interests include understanding the genetics of iron disorders, cell biology of iron transporters, functional consequences of disease-causing mutations, mechanisms involved in regulating iron homeostasis and the development of liver injury.

Yee-Joo Tan

Affiliation: National University of Singapore, Singapore

Biography: To be provided

Alexey Teplyakov

Affiliation: Hauptman-Woodward Medical Research Institute, USA

Biography: To be provided

Vinay Tergaonkar

Affiliation: Institute of Molecular and Cell Biology, A*Star Institute, Singapore
Biography: Vinay Tergaonkar obtained his Ph.D. (2001) through an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA. He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California. He joined the Institute of Molecular and Cell Biology (IMCB), Singapore, in late 2005 as Principal Investigator and became a Senior Principal Investigator in 2010 and Research Director in 2015. He is also a Professor at School of Medicine at National University of Singapore. He serves on Editorial Boards of 1) Science Advances (AAAS), 2) Molecular and Cellular Biology (American Society for Molecular Biology), 3) Biochemical Journal (Portland Press) 4) Critical Reviews in Oncology/Hematology (Elsevier Press), 5) BMC Research Notes (Biomed Central) and 6) Telomeres and Telomerase. Work from his lab has received international recognition including the British council development award (2014), the Premiers’ fellowship from Government of South Australia (2015) and University of Macau Distinguished Professorship (2019).

Georg C. Terstappen

Affiliation: OxStem, Oxford, UK

Biography: Since September 2018 Georg C. Terstappen is CSO of OxStem in Oxford, UK. From March 2017 until April 2018 Georg was Head of Platform Technologies and Science China and Neurosciences TA Portfolio Leader at GSK’s R&D Centre in Shanghai. Georg was also Co-Chair of the Strategic Governing Group Neurodegeneration of the Innovative Medicines Initiative and Vice-Chair of its strategy group InnoMedS. From 2011-2016 he was Director of Discovery Biology at AbbVie and from 2002-2010 CSO of Siena Biotech - a neuroscience drug discovery company he co-initiated. Georg has 25 years of experience in drug discovery, is an inventor/co-inventor of 14 patents and an author of more than 80 scientific publications. He previously worked at Bayer AG, GlaxoWellcome and GlaxoSmithKline and conducted research at the Max-Planck-Institute in Cologne and the Federal Research Centre Juelich for which he received his PhD in natural sciences in 1992.

David J. Timson

Affiliation: The University of Brighton, UK

Biography: David was born in Greater Manchester and studied biochemistry (BSc, PhD) at the University of Birmingham.  After post-doctoral work at the Universities of Oxford and Manchester, he became a lecturer in biochemistry at Queen’s University, Belfast.  He worked there for over 12 years, before leaving in 2015 to become Professor of Biochemistry and Head of the School of Pharmacy and Biomolecular Sciences at the University of Brighton.  His research interests are in protein biochemistry, particularly (i) how proteins “go wrong” in inherited metabolic diseases; (ii) studying metabolic enzymes and calcium binding proteins from parasitic worms as potential drug targets; (iii) investigating the enzymology of quinone oxidoreductases; (iv) altering the specificity of enzymes to exploit them as potential biocatalysts.

Mark D. Turner

Affiliation: Nottingham Trent University, UK

Biography: After completing his PhD in Medicine at the University of Liverpool, Dr Turner moved to the USA to undertake postdoctoral studies at The Scripps Research Institute, Harvard Medical School, and Albert Einstein College of Medicine. He then returned to the UK to take up a faculty appointment at Bart's and The London School of Medicine and Dentistry, before later moving to his current position at Nottingham Trent University.

Rietie Venter

Affiliation: University of South Australia, Australia

Biography: Rietie is currently the Head of Microbiology in the School of Pharmacy and Medical Sciences at the University of South Australia. Her research focuses on antimicrobial resistance in pathogenic microbes which is one of the most serious threats in healthcare today. Her group works on projects aimed at detecting antimicrobial resistance in clinical and environmental settings as well as understanding the factors that drive the rapid dissemination of antibiotic resistant organisms. She is also heading an antimicrobial drug discovery program aimed at finding new therapeutics against drug resistant pathogens.  Rietie obtained her BSc(Hons) and Master’s degrees with distinction from the University of the Free State in South Africa before securing a scholarship to do a PhD in the UK. After completing her PhD at the University of Leeds in the beautiful Yorkshire Dales, she moved to Cambridge, where she spent twelve years doing research on multidrug transporters, first as a post-doc and later running her own research group as a Royal Society Dorothy Hodgkin Fellow in the Department of Pharmacology. Not content with moving continents once in a lifetime, she left the ancient buildings and immaculate college lawns of Cambridge for sun and sea in Australia after sixteen years in the UK. 

Kong-Peng Lam

Affiliation: A*Star Bioprocessing Technology Institute, Singapore

Biography: Professor Kong-Peng Lam is currently Executive Director of the Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR) as well as Professor (with Tenure) at the National University of Singapore.  He is also Adjunct Professor at the School of Biological Sciences at Nanyang Technological University.  Dr Lam received his PhD training at Columbia University in the USA and did his postdoctoral training at the Institute for Genetics, University of Cologne in Germany where he worked on conditional gene knockout mouse models of diseases.  He is an immunologist by training and his research interests are in immune cell signalling, immunotherapy, host-pathogen interactions and biologics discovery and development. 

Ming Yang

Affiliation: Oklahoma State University, USA

Biography: Dr. Ming Yang is a plant cell and molecular biologist. His major contributions are in the areas of stomatal development, meiotic cell cycle progression, and cell morphogenesis in plants. He has investigated a number of Arabidopsis mutants that exhibit interesting phenotypes in the mentioned areas. His research emphasis is on detecting the effects of individual and combined mutations on cell morphology to gain insights into the molecular mechanisms. Stemming from his experimental work, Dr. Yang has also conducted theoretical investigations into the physical basis of biological rhythms; he proposed that slow diffusion of biomolecules could lead to short pauses in biochemical reactions, which in turn, produce long biological oscillations in a negative feedback loop. Dr. Yang’s group is currently investigating the functions of novel leucine-rich repeat receptor-like kinases in epidermal cell formation and proteins in meiotic checkpoint network in Arabidopsis. Dr. Yang also continues his theoretical work on various biological processes.

Jane Rosemary Allison

Affiliation: The University of Auckland, New Zealand

Biography: Jane obtained a BSc (Hons) from the University of Canterbury in 2003 and a PhD from Cambridge University in 2008, where she worked with Prof. Chris Dobson. After working as a postdoc with Prof. Wilfred van Gunsteren at ETH Zürich, she returned to New Zealand in 2012 to become a Lecturer at Massey University. She was awarded a Rutherford Discovery Fellowship in 2015, and in 2018, moved to the University of Auckland, where she is an Associate Professor and an Associate Investigator with the Maurice Wilkins Centre for Molecular Biodiscovery and the Biomolecular Interaction Centre at the University of Canterbury.

Tom Van Agtmael

Affiliation: University of Glasgow

Biography: Following his undergraduate training in Biochemistry at the University of Antwerp (Belgium), Dr. Van Agtmael obtained his PhD in molecular genetics at the Murdoch Childrens Research Institute in Melbourne (Australia). He then moved to the MRC Human Genetics Unit in Edinburgh for his post-doctoral training as an EU Marie Curie Fellow during which he identified the first vertebrate Col4a1 mutations and implicated type IV collagen in eye and kidney disease. Following a CVRI Wellcome Trust Fellowship at the University of Edinburgh, he was awarded a MRC New Investigator Research Grant to investigate the role of collagen IV in vascular biology. He then joined the University of Glasgow as a RCUK Fellow in Human Molecular Genetics where he established his research group within the Institute of Cardiovascular and Medical Sciences.

Atlanta Cook

Affiliation: University of Edinburgh

Biography: To be provided

Close Modal

or Create an Account

Close Modal
Close Modal